Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Actinogen Medical (ACW) is granted a Brazilian patent for its Alzheimer’s disease compound Xanamem
- The grant completes the “Webster 7” family grants, with protection across all major pharmaceutical markets
- The patents provide exclusive rights in these regions and offer protection to 2031, with options to extend by an additional five years
- On the market, Actinogen was up 1.28 per cent this afternoon, trading at 7.9 cents per share
Actinogen Medical (ACW) has been granted a Brazilian patent for its Alzheimer’s disease compound Xanamem.
The grant completes the “Webster 7” family grants, with protection across all major pharmaceutical markets, including the US, UK, European Union, Japan, China, Canada and Australia.
The patents provide exclusive rights in these regions and offer protection through to 2031, with options to extend by an additional five years.
CEO and Managing Director, Steven Gourlay, was pleased to have been granted the Brazilian patent.
“The addition of the Brazilian patent marks the completion of Xanamem’s composition of matter intellectual property (IP) portfolio in all major markets,” Dr Gourlay said.
“We expect that patent extensions, additional patents and regulatory mechanisms such as orphan designation will further extend its intellectual property protection.”
Actinogen filed for further patents last year, which are designed to extend patent protection for Xanamem and the company continues to follow other strategies to strengthen its IP position, such as paediatric development programs and orphan designations.
Last month, Actinogen enrolled its first patient in Part A of a two-trial targeting patients with mild cognitive impairment due to Alzheimer’s disease.
On the market, Actinogen was up 1.28 per cent this afternoon, trading at 7.9 cents per share at 2:34 pm AEST.
